UBS O'Connor’s Royalty Pharma RPRX Stock Holding History

UBS O'Connor’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-65,711	Closed	-$2.76M	–	635
2020 Q3	$2.76M	Buy	+65,711	New	+$2.82M	0.07%	156

Other funds holding RPRX

RWJF

Robert Wood Johnson Foundation Princeton, New Jersey $81M AUM 0.47% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

VCG

Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS O'Connor's RPRX Position: Q4 2020 in Review

UBS O'Connor sold out of Royalty Pharma (RPRX) in Q4 2020, closing a stake of 65,711 shares — an estimated $2.76M sold.

UBS O'Connor first reported a position in RPRX in Q3 2020 and held it in 1 quarter. The position peaked at $2.76M in Q3 2020. 199 funds tracked by Wall St. Rank hold RPRX as of Q4 2020.

UBS O'Connor reported no remaining Royalty Pharma position as of Q4 2020 after selling out during the quarter.
UBS O'Connor sold 65,711 Royalty Pharma shares in Q4 2020, an estimated $2.76M.
UBS O'Connor first reported a position in Royalty Pharma in Q3 2020 and held it in 1 quarter.
UBS O'Connor's Royalty Pharma position peaked at $2.76M in Q3 2020.
199 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2020.

Based on UBS O'Connor's 13F filing for Q4 2020, filed 17 Feb 2021.